Alpha lipoic acid (ALA, thioctic acid, lipoic acid) – sulfur-containing fatty acid found in small amounts in foods; synthesized in body in tiny amounts; serves as cofactor for mitochondrial enzymes; potent antioxidant. Unique property – both fat- and water-soluble (most antioxidants are one or the other); can work in different cellular environments. Endogenous but very small amounts; supplements provide much higher levels than dietary intake. Food sources – red meat, organ meats (small amounts), spinach, broccoli, brussels sprouts, tomatoes (insufficient for therapeutic effects). Mechanism – direct antioxidant (neutralizes free radicals); regenerates other antioxidants (vitamins C and E, glutathione); chelates heavy metals; mitochondrial cofactor; insulin signaling enhancement. Two enantiomers – R-ALA (natural form) and S-ALA; many supplements are racemic mix; R-ALA more bioavailable but more expensive. Medical use – Europe approved for diabetic peripheral neuropathy; U.S. sold as supplement (not FDA-approved for medical use); clinical use in Germany for decades. Particularly strong evidence for diabetic neuropathy. Meta-analyses (especially Ziegler 2004) show significant improvement in neuropathy symptoms – pain, burning, numbness, tingling. ALADIN trial (German) – 600 mg daily for 5 weeks improved symptoms. NATHAN-1 trial – 600 mg daily for 4 years showed sustained benefit. Both oral and IV ALA studied (IV more common in Europe). European clinical use established. Mechanism – antioxidant effect reduces oxidative stress in nerves; improves blood flow to nerves; mitochondrial function support. Blood sugar research – some studies suggest modest A1C reduction (0.3-0.5%); fasting glucose improvement; insulin sensitivity improvement. Effect modest; not comparable to medications. Other potential benefits – weight loss (small); blood pressure (modest); lipid profile improvements. Typical dosing – 600 mg daily (best-studied dose for neuropathy); some use 600 mg twice daily for 8 weeks then 600 mg daily; for blood sugar may use lower 300-600 mg. Form – racemic ALA most common; R-ALA more bioavailable. Take 30 min before meals optimizes absorption; with food if GI symptoms. Side effects usually mild – rash, itching, mild GI. Drug interactions few – monitor blood sugar with diabetes meds; thyroid medication absorption separate by 2+ hours.
ALA Properties
| Property | Detail |
|---|---|
| Type | Sulfur-containing fatty acid |
| Synthesis | Body makes small amounts; foods have very little |
| Solubility | BOTH fat- and water-soluble (unique) |
| Antioxidant capacity | Direct + regenerates vitamins C, E, glutathione |
| R vs racemic | R-ALA natural and more bioavailable; racemic cheaper |
| FDA | Supplement (US); approved drug for neuropathy in some EU countries |
| Cost | $10-30/month typical |
ALA Evidence for Diabetes Conditions
| Condition | Evidence Level |
|---|---|
| Diabetic peripheral neuropathy (symptoms) | Strong |
| Diabetic autonomic neuropathy | Moderate |
| Blood sugar/A1C | Modest (0.3-0.5% reduction) |
| Insulin sensitivity | Some evidence |
| Weight loss | Modest in some studies |
| Lipids | Some improvement |
| Blood pressure | Modest in some studies |
| Cardiovascular disease prevention | Limited |
Dosing Recommendations
- Diabetic neuropathy – 600 mg daily (most studied).
- Loading – 600 mg twice daily 8 weeks; then maintenance 600 mg daily.
- Blood sugar focus – 300-600 mg daily.
- 30 minutes before meals optimizes absorption.
- With food if GI symptoms.
- Choose racemic ALA (most studied; affordable) or R-ALA (more bioavailable, expensive).
- Onset 4-8 weeks for neuropathy symptoms.
- Don’t combine high-dose with other supplements without supervision.
Best Uses for Diabetes Patients
- Diabetic peripheral neuropathy with painful symptoms (strongest indication).
- Adjunct to standard neuropathy medications.
- Diabetic autonomic neuropathy.
- Modest blood sugar effects (adjunct, not primary).
- Antioxidant support.
- Possibly metabolic syndrome.
- Consider with poor neuropathy response to other treatments.
Cautions and Considerations
- Discuss with provider before adding.
- Quality supplement matters.
- Pregnancy/breastfeeding – limited safety data.
- Children – not studied.
- Thyroid medication separate by 2+ hours.
- Monitor blood sugar with diabetes medications.
- Don’t replace prescribed medications.
- Side effects usually mild (rash, GI).
- Rare biotin deficiency with long-term use.
- Standardized supplement preferred.
The Bottom Line
Alpha lipoic acid (ALA, thioctic acid, lipoic acid) – sulfur-containing fatty acid found in small amounts in foods; synthesized in body in tiny amounts; serves as cofactor for mitochondrial enzymes; potent antioxidant. Unique property – both fat- and water-soluble; can work in different cellular environments. Two enantiomers – R-ALA (natural, more bioavailable) and S-ALA; many supplements racemic mix. Medical use – Europe approved for diabetic peripheral neuropathy; U.S. sold as supplement; clinical use in Germany for decades. Particularly strong evidence for diabetic neuropathy – meta-analyses show significant improvement in neuropathy symptoms (pain, burning, numbness, tingling); ALADIN trial showed 600 mg daily for 5 weeks improved symptoms; NATHAN-1 trial showed sustained benefit. Mechanism – antioxidant effect reduces oxidative stress in nerves; improves blood flow to nerves; mitochondrial function support. Blood sugar research – modest A1C reduction (0.3-0.5%); fasting glucose improvement; insulin sensitivity improvement; not comparable to medications. Typical dosing – 600 mg daily (best-studied dose for neuropathy); 30 minutes before meals optimizes absorption; with food if GI symptoms. Side effects usually well-tolerated – possible rash, itching, mild GI symptoms. Drug interactions few – monitor blood sugar with diabetes meds; thyroid medication absorption may be affected (separate by 2+ hours). Most appropriate use cases – diabetic peripheral neuropathy with painful symptoms (strongest evidence; reasonable adjunct to standard treatments like duloxetine, pregabalin, gabapentin); diabetic autonomic neuropathy; modest blood sugar effects (adjunct not primary); antioxidant support. Less appropriate – replacing prescribed neuropathy medications; type 1 diabetes (insulin primary); pregnancy/breastfeeding (limited safety data); children (not studied); high-dose long-term without monitoring. Discuss with provider before adding. Quality supplement matters – reputable brands, standardized to ALA content, third-party tested (NSF, USP). For adults with type 2 diabetes – ALA is one of more evidence-based supplements for diabetic neuropathy symptoms; reasonable adjunct in appropriate cases; modest A1C effects; well-tolerated generally; not substitute for foundational treatments (blood sugar control, foot care, prescribed neuropathy medications). See our broader diabetes supplements guide for context.
